Physician profile
Jonathan Humphrey
NPI 1689644866
$18,265.49
in general payments reported to CMS, 2019-2025
90 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,519 · 2020: $1,680 · 2021: $2,850 · 2022: $2,737 · 2023: $2,430 · 2024: $3,610 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,389 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,389.49 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,840.68 | 2019-2025 | |
| Pfizer INC. | $1,423.31 | 2019-2025 | |
| Amgen INC. | $1,069.57 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $839.32 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Allergan, INC. | $762.05 | 2019-2020 | |
| Esperion Therapeutics, INC. | $686.90 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $651.59 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Supernus Pharmaceuticals, INC. | $628.23 | 2022-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.98 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $570.73 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $514.76 | 2019-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $512.46 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $488.70 | 2019-2025 | |
| Novo Nordisk INC | $467.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $334.46 | 2022-2025 | Caplyta |
Show all 90 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.